Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acalabrutinib in hospitalized COVID-19 patients
NCT04380688Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Jun 2020
- Primary completion
- Nov 2020
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of acalabrutinib tablet (Variant 1) in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by AstraZeneca. Primary endpoints: Percentage of Participants Alive and Free of Respiratory Failure at Day 28 and Number of Participants With Adverse Events and Serious Adverse Events. Started Jun 2020; status: completed.
02
Drugs
acalabrutinib tablet (Variant 1)
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04380688.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04380688.